Keywords: fda, delays, lilly, icos, cialis, erectile, dysfunction
FDA delays Lilly ICOS' Cialis for erectile dysfunction; new trials required
Article | 06 May 2002
Pfizer looks set to have the oral market for erectile dysfunction in theUSA to itself for a little longer, following ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
